Loading company…
Newish develops antitumor DNA vaccine drugs.
Newish operates nucleic acid and T-cell therapeutic platforms for developing tumor vaccines. Founded in 2014, the company is based in Beijing, China. It raised CNY 100 million in Series B funding led by Shanghai Kangcheng Investment Management in June 2026.
Funding rounds, investors and people for this company come from licensed data. A free account shows the first rows of each section; an approved contribution opens every profile in full.
Sign in